ECM
PTGX icon

Everence Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Everence Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
+1,924
New +$201K 0.01% 751
2024
Q4 		– Sell
-7,050
Closed -$317K – 991
2024
Q3 		$317K Buy
+7,050
New +$285K 0.02% 566

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Everence Capital Management's PTGX Position: Q2 2026 in Review

Everence Capital Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 1,924 shares worth $236K. The stake represents 0.01% of the portfolio and ranks #751 among its holdings. This is a return to the name: Everence Capital Management previously reported a position in PTGX as recently as Q3 2024.

Everence Capital Management first reported a position in PTGX in Q3 2024 and has held it in 2 quarters since. The position peaked at $317K in Q3 2024. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Everence Capital Management held 1,924 shares of Protagonist Therapeutics worth $236K as of Q2 2026.
  • Protagonist Therapeutics was a new Everence Capital Management position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Everence Capital Management's portfolio in Q2 2026, its #751 holding.
  • Everence Capital Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Everence Capital Management's Protagonist Therapeutics position peaked at $317K in Q3 2024.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.